Back to bill feed
118-s-3311Committee
Sign in to get alerts

American Made Pharmaceuticals Act of 2023

Read the record. Not the rhetoric.

See how your representatives voted on this bill.

DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.

Alignment with your views

Sign in and take the values quiz to see how this bill lines up with what you've said.

Summary

Official CRS summary

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Values analysis

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.

How your representatives voted

Sign in to see how your representatives voted on this bill.